Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

American Oriental’s Financials Disappoint Again

publication date: Nov 17, 2009
View a Printer Friendly version of this page, allowing you to print the page.

American Oriental Bioengineering (广西博科药业)reported its Q3 revenues rose 12% to $78.8 million but net income fell 39% to $10.0 million. Though the company had a list of reasons for the decline, the mixed nature of American Oriental’s financial disclosures – higher revenues and lower profits – have been a fact of life all year for the company. More details...

Stock Symbol: (NYSE: AOB)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China